ENTRUST-GLOBAL
14.6.2021 21:15:03 CEST | Business Wire | Press release
The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced the completion of the acquisition of the Aviation Investment and Asset Management business from DVB Bank Group, resulting in the formation of Deucalion Aviation Limited (“Deucalion” or the “Company”). Deucalion is an innovative global platform with world class aviation expertise and the ability to invest across the capital spectrum to provide solutions to airlines and aviation investors.
Led by Jon Skirrow and Stephan Sayre, with the support of EnTrust Global and SVPGlobal, Deucalion is a servicer for over 170 aircraft on lease to 86 airlines with clients including banks, investors, financiers and lessors.
Jon Skirrow, Co-CEO & COO said: “This new investment creates a platform with collaboration at its heart to enable us to continue and expand our world-leading services to airlines and investors”.
Stephan Sayre, Co-CEO & CIO added: “EnTrust and SVPGlobal share our vision to provide transformational financing and investment solutions. Together, we will be able to significantly strengthen our offering of innovative financing solutions to airline and leasing clients globally in the current environment”.
Victor Khosla, Founder & CIO of SVPGlobal, said: “Deucalion is a top-tier aviation platform with an experienced management team, a global footprint, and an impressive track record that spans almost two decades of managing complex aviation projects. We look forward to working with the Deucalion team as we continue to capitalize on the current market opportunity.”
John Morabito, Senior Managing Director and Portfolio Manager of EnTrust Global’s Blue Sky Aviation strategy, said: “The Deucalion team, led by Jon and Stephan, has extensive institutional knowledge and experience in the aviation industry. By combining our groups’ strengths, relationships, and capabilities, we are positioned to provide differentiated financing solutions to the global aviation industry.”
About Deucalion Aviation Limited
Deucalion Aviation Limited is a servicer for over 170 aircraft on lease to 86 airlines with clients including banks, investors, financiers and lessors and is headquartered in London with offices in Europe, Asia and America. Led by Jon Skirrow and Stephan Sayre, the Deucalion team is composed of over 45 marketing, commercial finance, origination and technical professionals with experience throughout multiple aviation cycles. www.deucalion.com
About EnTrust Global
EnTrust Global is a leading alternative asset management firm with approximately $19.5 billion in total assets.* Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 48 countries and has approximately $11 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 10 offices worldwide and is headquartered in New York and London.
*As of March 31, 2021. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.
About Strategic Value Partners
SVPGlobal is a global investment firm focused on special situations and private equity opportunities with more than $15 billion in assets under management. The firm, established by Victor Khosla in 2001, uses a combination of sourcing, financial, and operational expertise. SVP has 128 employees, including 50 investment professionals, across its main offices in Greenwich (CT), London and Tokyo.
Learn more at www.svpglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom